Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has received a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $41.75.

Several analysts have issued reports on AGIO shares. Truist Financial cut their price objective on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. Citigroup lifted their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Finally, HC Wainwright upped their price target on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the sale, the insider directly owned 54,645 shares of the company’s stock, valued at $1,665,579.60. The trade was a 35.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AGIO. Tidal Investments LLC boosted its position in Agios Pharmaceuticals by 12.0% during the 2nd quarter. Tidal Investments LLC now owns 16,100 shares of the biopharmaceutical company’s stock worth $597,000 after acquiring an additional 1,724 shares during the period. Engineers Gate Manager LP increased its holdings in shares of Agios Pharmaceuticals by 86.4% in the 2nd quarter. Engineers Gate Manager LP now owns 53,912 shares of the biopharmaceutical company’s stock valued at $2,001,000 after purchasing an additional 24,992 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $47,000. Squarepoint Ops LLC lifted its position in shares of Agios Pharmaceuticals by 53.7% in the second quarter. Squarepoint Ops LLC now owns 321,138 shares of the biopharmaceutical company’s stock worth $11,917,000 after purchasing an additional 112,250 shares in the last quarter. Finally, Allworth Financial LP lifted its position in shares of Agios Pharmaceuticals by 2,798.5% in the second quarter. Allworth Financial LP now owns 1,971 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 1,903 shares in the last quarter.

Agios Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ AGIO opened at $32.58 on Tuesday. The stock’s fifty day simple moving average is $33.81 and its 200 day simple moving average is $32.33. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -4.65 and a beta of 0.60. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The company had revenue of $44.75 million for the quarter, compared to analysts’ expectations of $26.39 million. As a group, analysts anticipate that Agios Pharmaceuticals will post -5.82 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults.